Evidence map›Paper›PMID 30305931›Full record

ArticleRMD open2018

Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: experiences from the nationwide NOCAR project.

Eirik Ikdahl, Silvia Rollefstad, Grunde Wibetoe, Anne Salberg, Frode Krøll, Kjetil Bergsmark, Tore K Kvien, Inge C Olsen, Dag Magnar Soldal, Gunnstein Bakland and 5 more

Open access · goldAbstract read
In one paragraph

Article in RMD open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Eirik IkdahlDepartment of Rheumatology, Preventive Cardio-Rheuma Clinic, Oslo, Norway.
Silvia RollefstadDepartment of Rheumatology, Preventive Cardio-Rheuma Clinic, Oslo, Norway.
Grunde WibetoeDepartment of Rheumatology, Preventive Cardio-Rheuma Clinic, Oslo, Norway.
Anne SalbergDepartment of Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway.
Frode KrøllDepartment of Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway.
Kjetil BergsmarkDepartment of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
Tore K KvienDepartment of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
Inge C OlsenDepartment of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
Dag Magnar SoldalDepartment of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway.
Gunnstein BaklandDepartment of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway.
Åse LexbergDepartment of Rheumatology, Drammen Hospital, Drammen, Norway.
Clara G GjesdalDepartment of Rheumatology, Haukeland University Hospital, Bergen, Norway.
Christian GulsethDepartment of Rheumatology, Betanien Hospital, Skien, Norway.
Glenn HaugebergDepartment of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway.
Anne Grete SembDepartment of Rheumatology, Preventive Cardio-Rheuma Clinic, Oslo, Norway.
Diakonhjemmet Hospital · NOHospital of Southern Norway · NOBetanien Hospital · NODrammen Hospital · NOHaukeland University Hospital · NOUniversity Hospital of North Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe European League Against Rheumatism recommends implementing cardiovascular disease (CVD) risk assessments for patients with inflammatory joint diseases (IJDs) into clinical practice. Our goal was to design a structured programme for CVD risk assessments to be implemented into routine rheumatology outpatient clinic visits.

methodsThe NOrwegian Collaboration on Atherosclerosis in patients with Rheumatic joint diseases (NOCAR) started in April 2014 as a quality assurance project including 11 Norwegian rheumatology clinics. CVD risk factors were recorded by adding lipids to routine laboratory tests, self-reporting of CVD risk factors and blood pressure measurements along with the clinical joint examination. The patients' CVD risks, calculated by the European CVD risk equation SCORE, were evaluated by the rheumatologist. Patients with high or very high CVD risk were referred to their primary care physician for initiation of CVD preventive measures.

resultsData collection (autumn 2015) showed that five of the NOCAR centres had implemented CVD risk assessments. There were 8789 patients eligible for CVD risk evaluation (rheumatoid arthritis (RA), 4483; ankylosing spondylitis (AS), 1663; psoriatic arthritis (PsA), 1928; unspecified and other forms of spondyloarthropathies (SpA), 715) of whom 41.4 % received a CVD risk assessment (RA, 44.7%; AS, 43.4%; PsA, 36.3%; SpA, 30.6%). Considerable differences existed in the proportions of patients receiving CVD risk evaluations across the NOCAR centres.

conclusionPatients with IJD represent a patient group with a high CVD burden that seldom undergoes CVD risk assessments. The NOCAR project lifted the offer of CVD risk evaluation to over 40% in this high-risk patient population.

Indexed as

ankylosing spondylitiscardiovascular diseasehealth services researchpsoriatic arthritisrheumatoid arthritis

Identifiers

PMID30305931
PMCPMC6173264
OpenAlexW2894766530

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.